Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plixorafenib in Participants With Cancer Harboring BRAF Alterations
NCT05503797Phase 2Recruiting
- Sponsor
- Fore Biotherapeutics
- Start
- Feb 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of plixorafenib in solid tumor, central nervous system tumor, sponsored by Fore Biotherapeutics. Started Feb 2023; status: recruiting.
02
Drugs
plixorafenib
03
Conditions
solid tumorcentral nervous system tumor
Beyond the preview
Go deeper on NCT05503797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05503797.